Targeting thromboinflammation in COVID-19 - A narrative review of the potential of C1 inhibitor to prevent disease progression.

"Conflict of interest Dr. Trendelenburg reports receiving grants from the Swiss National Science Foundation, Roche, Novartis, and Idorsia outside of the submitted work. Dr. Osthoff reports receiving grants from the Swiss National Science Foundation and Pharming Technologies B.V. for the investigator-initiated trial of rhC1INH in COVID-19 (ClinicalTrials.gov Identifier: NCT04414631), and from the Botnar Research Centre for Child Health outside the submitted work, and consulting fees from Pharming Technologies B.V. No other disclosures or conflicting interests with regards to this work have been reported."

"Funding This work was supported the Swiss National Science Foundation (10.13039/501100001711SNSF) within the framework of the National Research Program "Covid-19" (NRP 78) Grant-N° 40780_198403. The funders had no role in collection, analysis and interpretation of data, preparation of the manuscript, or the decision to submit the manuscript for publication."